144 related articles for article (PubMed ID: 36309400)
1. Complete Response to Nivolumab of Resected Adenocarcinoma NOS With Parotid Gland Origin and Lung Metastasis.
Negishi Y; Okamoto I; Ueda Y; Sato H; Tanigawa M; Nagao T; Tsukahara K
In Vivo; 2022; 36(6):2840-2843. PubMed ID: 36309400
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of anti-PD-1 therapy in a patient with brain metastasis of parotid carcinoma: A case report.
Takemoto K; Miyahara N; Chikuie N; Hamamoto T; Ishino T; Ueda T; Takeno S
Auris Nasus Larynx; 2019 Oct; 46(5):813-817. PubMed ID: 30442438
[TBL] [Abstract][Full Text] [Related]
3. [Oncocytic carcinoma of the parotid gland: a case report].
Jiang R; Wang X; Tong L
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jul; 29(13):1223-5. PubMed ID: 26540931
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab for recurrent or metastatic head and neck cancer patients with non-squamous cell carcinoma and/or a primary subsite excluded from CheckMate141, a retrospective study.
Ueda Y; Okano S; Enokida T; Fujisawa T; Ito K; Sato M; Tanaka H; Wada A; Tahara M
Oral Oncol; 2022 Jul; 130():105932. PubMed ID: 35636078
[TBL] [Abstract][Full Text] [Related]
5. Tumor to Tumor Metastasis from Adenocarcinoma Not Otherwise Specified of the Parotid Gland to Uterine Leiomyoma: Presentation of a Unique Case.
Psarris A; Koufopoulos N; Grivas A; Papatheodorou DC; Khaldi L
Cureus; 2020 Jan; 12(1):e6789. PubMed ID: 32140349
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological features and treatment outcomes of the rare, salivary duct carcinoma of parotid gland.
Al-Qahtani KH; Tunio MA; Bayoumi Y; Gurusamy VM; Bahamdain FA; Fatani H
J Otolaryngol Head Neck Surg; 2016 May; 45(1):32. PubMed ID: 27184361
[TBL] [Abstract][Full Text] [Related]
7. Microsecretory Adenocarcinoma: A Novel Salivary Gland Tumor Characterized by a Recurrent MEF2C-SS18 Fusion.
Bishop JA; Weinreb I; Swanson D; Westra WH; Qureshi HS; Sciubba J; MacMillan C; Rooper LM; Dickson BC
Am J Surg Pathol; 2019 Aug; 43(8):1023-1032. PubMed ID: 31094920
[TBL] [Abstract][Full Text] [Related]
8. Case Report: Complete Response of Recurrent and Metastatic Cystadenocarcinoma of the Parotid Gland With a Single Course of Combined Nivolumab and Ipilimumab Therapy.
Nakamura Y; Nakayama M; Nishimura B; Okiyama N; Tanaka R; Ishitsuka Y; Matsumoto S; Fujisawa Y
Front Oncol; 2021; 11():618201. PubMed ID: 33718174
[TBL] [Abstract][Full Text] [Related]
9. Utility of neck dissection for management of carcinoma of the parotid gland.
Kaura A; Kennedy RA; Ali S; Odell E; Simo R; Jeannon JP; Oakley R
Br J Oral Maxillofac Surg; 2019 Dec; 57(10):1039-1043. PubMed ID: 31564483
[TBL] [Abstract][Full Text] [Related]
10. [Distant metastases of malignant salivary gland carcinoma after treated by
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Jun; 49(3):547-580. PubMed ID: 28628162
[TBL] [Abstract][Full Text] [Related]
11. Basal cell adenocarcinoma of the parotid gland with rare scalp metastasis: a case report.
Eroglu A; Cuce F; Simsek H; Topuz AK; Duz B
Turk Neurosurg; 2015; 25(1):177-9. PubMed ID: 25640567
[TBL] [Abstract][Full Text] [Related]
12. Management of nasopharyngeal salivary gland malignancy.
Schramm VL; Imola MJ
Laryngoscope; 2001 Sep; 111(9):1533-44. PubMed ID: 11568602
[TBL] [Abstract][Full Text] [Related]
13. Sustained response of HER2-positive metastatic salivary adenocarcinoma, not otherwise specified, treated with trastuzumab.
Ghazali N; Parker L; Settle K; Lubek JE
Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Sep; 122(3):292-9. PubMed ID: 27289263
[TBL] [Abstract][Full Text] [Related]
14. Metastatic SMARCB1 Deficient Skin Carcinoma With Neuroendocrine Differentiation in the Parotid Glands Clinically Mimicking Primary Salivary Gland Malignancy: Unusual Case With Diagnostic Pitfalls.
Fang F; Zhang QI; Pinto-Cuberos JM; Lai J
Anticancer Res; 2022 Aug; 42(8):3971-3974. PubMed ID: 35896245
[TBL] [Abstract][Full Text] [Related]
15. Basal cell adenocarcinoma of the buccal minor salivary gland with liver metastases.
Chen S; Yang S; Chen X
Ann Saudi Med; 2015; 35(4):318-20. PubMed ID: 26497713
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab as a Promising Treatment Option for Metastatic Salivary Duct Carcinoma.
Bugia L; Jungbauer F; Zaubitzer L; Hörner C; Merx K; Yasser AM; Germann T; Lammert A; Scherl C; Rotter N; Affolter A
J Immunother; 2024 Mar; ():. PubMed ID: 38545827
[TBL] [Abstract][Full Text] [Related]
17. Carcinoma ex pleomorphic adenoma of the parotid gland: a multi-institutional retrospective analysis in the Northern Japan Head and Neck Cancer Society.
Suzuki M; Matsuzuka T; Saijo S; Takahara M; Harabuchi Y; Okuni T; Himi T; Kakizaki T; Fukuda S; Yamada K; Nagahashi T; Abe T; Shinkawa H; Katagiri K; Sato H; Fukui N; Ishikawa K; Suzuki T; Kobayashi T; Saito D; Saijo S; Tateda M; Hashimoto S; Ishida A; Kakehata S; Suzuki O; Hashimoto Y; Omori K
Acta Otolaryngol; 2016 Nov; 136(11):1154-1158. PubMed ID: 27295405
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
Locati LD; Perrone F; Cortelazzi B; Bergamini C; Bossi P; Civelli E; Morosi C; Lo Vullo S; Imbimbo M; Quattrone P; Dagrada GP; Granata R; Resteghini C; Mirabile A; Alfieri S; Orlandi E; Mariani L; Saibene G; Pilotti S; Licitra L
Eur J Cancer; 2016 Dec; 69():158-165. PubMed ID: 27821319
[TBL] [Abstract][Full Text] [Related]
19. Patterns of lymph node metastasis of parotid cancer.
Shinomiya H; Otsuki N; Yamashita D; Nibu K
Auris Nasus Larynx; 2016 Aug; 43(4):446-50. PubMed ID: 26656731
[TBL] [Abstract][Full Text] [Related]
20. Metastatic malignant melanoma mimicking a salivary gland basaloid neoplasm after treatment with nivolumab.
Lajara S; Landau M
Diagn Cytopathol; 2021 Sep; 49(9):E370-E373. PubMed ID: 34174024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
